In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...

Prostate cancer stands as the second most commonly diagnosed cancer in men worldwide, following lung cancer, according to the American Cancer Society. Alarming projections by the National Cancer ...

There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...